Sana Biotechnology Ownership
| SANA Stock | USD 2.45 0.03 1.21% |
Shares in Circulation | First Issued 2019-12-31 | Previous Quarter 234.4 M | Current Value 235.4 M | Avarage Shares Outstanding 179.7 M | Quarterly Volatility 34.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Sana |
Sana Stock Ownership Analysis
About 92.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.87. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sana Biotechnology recorded a loss per share of 1.4. The entity had not issued any dividends in recent years. Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company was incorporated in 2018 and is headquartered in Seattle, Washington. Sana Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 461 people. To find out more about Sana Biotechnology contact Steven MD at 206 701 7914 or learn more at https://www.sana.com.Besides selling stocks to institutional investors, Sana Biotechnology also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Sana Biotechnology's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Sana Biotechnology's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Sana Biotechnology Quarterly Liabilities And Stockholders Equity |
|
Sana Biotechnology Insider Trades History
About 9.0% of Sana Biotechnology are currently held by insiders. Unlike Sana Biotechnology's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Sana Biotechnology's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Sana Biotechnology's insider trades
Sana Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sana Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sana Biotechnology backward and forwards among themselves. Sana Biotechnology's institutional investor refers to the entity that pools money to purchase Sana Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Associates, Inc. | 2024-06-30 | 3.1 M | Alphabet Inc | 2024-09-30 | 2.8 M | Baker Bros Advisors Lp | 2024-09-30 | 2.4 M | Integral Health Asset Management, Llc | 2024-09-30 | 1.8 M | Boxer Capital Llc | 2024-09-30 | 1.5 M | Northern Trust Corp | 2024-09-30 | 1.1 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1 M | Jpmorgan Chase & Co | 2024-06-30 | 951.6 K | Fmr Inc | 2024-09-30 | 31.6 M | Flagship Ventures Management, Inc. | 2024-06-30 | 25 M |
Sana Biotechnology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sana Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sana Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sana Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sana Biotechnology Outstanding Bonds
Sana Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sana Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sana bonds can be classified according to their maturity, which is the date when Sana Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Sana Biotechnology Corporate Filings
| 21st of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 22nd of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sana Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sana Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sana Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sana Biotechnology Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Return On Assets (0.31) | Return On Equity (0.93) |
The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.